These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 11223430)

  • 1. Chymase bound to heparin is resistant to its natural inhibitors and capable of proteolyzing high density lipoproteins in aortic intimal fluid.
    Lindstedt L; Lee M; Kovanen PT
    Atherosclerosis; 2001 Mar; 155(1):87-97. PubMed ID: 11223430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid.
    Lindstedt L; Lee M; Castro GR; Fruchart JC; Kovanen PT
    J Clin Invest; 1996 May; 97(10):2174-82. PubMed ID: 8636396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of rat mast cell protease 1 activity. Protease inhibition is prevented by heparin proteoglycan.
    Pejler G; Berg L
    Eur J Biochem; 1995 Oct; 233(1):192-9. PubMed ID: 7588746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolysis and fusion of low density lipoprotein particles independently strengthen their binding to exocytosed mast cell granules.
    Paananen K; Kovanen PT
    J Biol Chem; 1994 Jan; 269(3):2023-31. PubMed ID: 8294453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of pre beta 1LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma.
    Lee M; von Eckardstein A; Lindstedt L; Assmann G; Kovanen PT
    Arterioscler Thromb Vasc Biol; 1999 Apr; 19(4):1066-74. PubMed ID: 10195937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degradation of human anaphylatoxin C3a by rat peritoneal mast cells: a role for the secretory granule enzyme chymase and heparin proteoglycan.
    Gervasoni JE; Conrad DH; Hugli TE; Schwartz LB; Ruddy S
    J Immunol; 1986 Jan; 136(1):285-92. PubMed ID: 3510005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor: enhancement of the interaction by heparin.
    Walter M; Plotnick M; Schechter NM
    Arch Biochem Biophys; 1996 Mar; 327(1):81-8. PubMed ID: 8615699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chymase-dependent angiotensin II formation in human vascular tissue.
    Takai S; Jin D; Sakaguchi M; Miyazaki M
    Circulation; 1999 Aug; 100(6):654-8. PubMed ID: 10441104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactoferrin regulates the activity of heparin proteoglycan-bound mast cell chymase: characterization of the binding of heparin to lactoferrin.
    Pejler G
    Biochem J; 1996 Dec; 320 ( Pt 3)(Pt 3):897-903. PubMed ID: 9003378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mast cell--a potential link between inflammation and cellular cholesterol deposition in atherogenesis.
    Kovanen PT
    Eur Heart J; 1993 Dec; 14 Suppl K():105-17. PubMed ID: 8131778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density-lipoprotein binding by mast-cell granules. Demonstration of binding of apolipoprotein B to heparin proteoglycan of exocytosed granules.
    Kokkonen JO; Kovanen PT
    Biochem J; 1987 Jan; 241(2):583-9. PubMed ID: 3593208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol.
    Lee M; Sommerhoff CP; von Eckardstein A; Zettl F; Fritz H; Kovanen PT
    Arterioscler Thromb Vasc Biol; 2002 Dec; 22(12):2086-91. PubMed ID: 12482839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chymase-containing mast cells in human arterial intima: implications for atherosclerotic disease.
    Kovanen PT
    Heart Vessels; 1997; Suppl 12():125-7. PubMed ID: 9476562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mast cell chymase in complex with heparin proteoglycan is regulated by protamine.
    Pejler G
    FEBS Lett; 1996 Apr; 383(3):170-4. PubMed ID: 8925890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism by which heparin proteoglycan modulates mast cell chymase activity.
    Pejler G; Sadler JE
    Biochemistry; 1999 Sep; 38(37):12187-95. PubMed ID: 10508424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human skin chymotrypsin-like proteinase chymase. Subcellular localization to mast cell granules and interaction with heparin and other glycosaminoglycans.
    Sayama S; Iozzo RV; Lazarus GS; Schechter NM
    J Biol Chem; 1987 May; 262(14):6808-15. PubMed ID: 3553192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of copper-mediated oxidation of LDL by rat serosal mast cells. A novel cellular protective mechanism involving proteolysis of the substrate under oxidative stress.
    Lindstedt KA; Kokkonen JO; Kovanen PT
    Arterioscler Thromb; 1993 Jan; 13(1):23-32. PubMed ID: 8422337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mast cell granule-mediated uptake of low density lipoproteins by macrophages: a novel carrier mechanism leading to the formation of foam cells.
    Kovanen PT
    Ann Med; 1991; 23(5):551-9. PubMed ID: 1756025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors.
    Schechter NM; Sprows JL; Schoenberger OL; Lazarus GS; Cooperman BS; Rubin H
    J Biol Chem; 1989 Dec; 264(35):21308-15. PubMed ID: 2592376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of mast cell granules.
    Lindstedt KA; Kovanen PT
    Curr Protoc Cell Biol; 2006 Jan; Chapter 3():Unit 3.16. PubMed ID: 18228484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.